

# Supporting Information

## Preparation and characterization of phospholipid-conjugated indocyanine green as a near-infrared probe

**Akiko Suganami<sup>a</sup>, Taro Toyota<sup>a,b</sup>, Shigetoshi Okazaki<sup>c</sup>, Kengo Saito<sup>d</sup>, Katsuhiko Miyamoto<sup>e</sup>, Yasunori Akutsu<sup>f</sup>, Hiroshi Kawahira<sup>g</sup>, Akira Aoki<sup>h</sup>, Yutaka Muraki<sup>h</sup>, Tomoyuki Madono<sup>h</sup>, Hideki Hayashi<sup>g</sup>, Hisahiro Matsubara<sup>f</sup>, Takashige Omatsu<sup>e</sup>, Hiroshi Shirasawa<sup>d</sup>, Yutaka Tamura<sup>a,\*</sup>**

<sup>a</sup> Department of Bioinformatics, Chiba University

<sup>b</sup> The University of Tokyo

<sup>c</sup> Hamamatsu University School of Medicine

<sup>d</sup> Department of Molecular Virology, Chiba University

<sup>e</sup> Department of Image and Material Science, Chiba University

<sup>f</sup> Department of Frontier Surgery, Chiba University

<sup>g</sup> Research Center for Frontier Medical Engineering, Chiba University

<sup>h</sup> Yamada Chemical Co., Ltd.

## Table of Contents

<b>Materials and Methods</b> .....	S3
Molecular Modeling .....	S3
Syntheses .....	S3
NMR Measurements .....	S6
FTIR Measurements .....	S6
HPLC Analysis .....	S6
UV-vis Fluorescence Spectroscopy .....	S6
Singlet Oxygen Measurements .....	S7
Measurement of Photothermal Properties .....	S7
Preparation of Liposomes .....	S8
Gel-filtration Chromatography .....	S9
Measurement of Particle Size .....	S9
Biodistribution of LP-iDOPE by Liposome Formulas.....	S9
<b>Results</b> .....	S10
Molecular Modeling: Figure S1.....	S10
NMR Measurements: Figure S2 .....	S11
NMR Measurements: Figure S3 .....	S12
FTIR Measurements: Figure S4.....	S13
FTIR Measurements: Table S1 .....	S13
FTIR Measurements: Figure S5.....	S14
FTIR Measurements: Table S2.....	S14
HPLC Analysis Figure: S6 .....	S15
Singlet Oxygen Measurements: Figure S7 .....	S16
Dynamic Light-scattering Measurements: Figure S8.....	S17
Gel-filtration Chromatograph: Figure S9.....	S18

## Materials and Methods

### Molecular Modeling

The three-dimensional structure of ICG was constructed using MOE (version 2009, CCG Inc., Montreal, Canada) according to PubChem Compound CID 11967809 (National Center for Biotechnology Information, Bethesda MD, USA). The three-dimensional structure of DOPE was constructed using VMD (<http://www.ks.uiuc.edu/>). Then, the three-dimensional structures of ICG and DOPE were used to construct that of iDOPE using the build command in MOE. Molecular mechanics calculations were performed to obtain the local minimum structures of ICG, DOPC, and iDOPE, using the AMBER99 force field in MOE. Then, the lipophilic colors of the surfaces of ICG, DOPC, and iDOPE were calculated from the Wildman and Crippen SlogP parameter in MOE.

### Syntheses

iDOPE was prepared as shown in Scheme 1. The ICG fluorophore was synthesized from a single starting material, 2,3,3-trimethyl-4,5-benzo-3*H*-indole (**1**). **1** (3.1 g, 15 mmol) was added to acetonitrile (10 mL) with 3-bromo-1-propionic acid (1.5 g, 9.8 mmol), and the reaction solution was stirred at 65 °C for 16 h and then cooled to room temperature. Ethyl acetate (50 mL) was then added to the solution and the product, 2,3,3-trimethyl-1-(2-carboxyethyl)-4,5-benzoindolium bromide (**2**), was separated by filtration and rinsed with acetone, giving **1** as gray crystals (1.68 g, 47%). Then **1** (3.1 g, 15 mmol) and 1,4-butane sultone (2.1 g, 15 mmol) were mixed in a round-bottomed flask (25 mL) under a nitrogen atmosphere, and the reaction mixture was stirred at 80 °C for 4 h and then cooled to room temperature. On addition of acetone to the reaction

mixture the residue dissolved, and the product was crystallized. The reaction product, 2,3,3-trimethyl-1-(sulfobutyl)-4,5-benzoindolium inner salt (**3**), was separated by filtration and rinsed with acetone to give **3** as gray crystals (1.17 g, 23%). A mixture of **3** (1.04 g, 3.0 mmol) and glutacanaldehyde dianil hydrogen chloride salt (0.94 g, 3.3 mmol) was stirred at 120 °C for 1 h and then cooled to room temperature to crystallize the product, 2-(6-acetoanilido-1,3,5-hexatrienyl)-3,3-dimethyl-1-(sulfobutyl)-4,5-benzo[*e*]indolium inner salt (**4**). This salt was separated by filtration and rinsed with acetone to give **4** as dark-purple crystals (0.97 g, 58%). A pyridine solution (8 mL) of **2** (0.55 g, 1.5 mmol) and **4** (0.80 g, 1.5 mmol) was stirred at 50 °C for 45 min, and then cooled to room temperature. The reaction mixture was condensed under reduced pressure, and then distilled water (20 mL) and 10% HCl were added to adjust the pH to 3–4. The crude product was filtered from the reaction mixture and dried. After crystallization using methanol/chloroform (volume ratio: 5/1, 20 mL) and recrystallization in methanol/chloroform, the product, 4-(2-((1*E*,3*E*,5*E*,7*E*)-7-(3-(2-carboxyethyl)-1,1-dimethyl-1*H*-benzo[*e*]indol-2(3*H*)-ylidene)hepta-1,3,5-trienyl)-1,1-dimethyl-1*H*-benzo[*e*]indolium-3-yl)butane-1-sulfonic acid (**5**), was obtained as dark-green crystals (0.38 g, 37%). In a mixed organic solvent of acetonitrile (3 mL) and chloroform (10 mL), **5** (0.5 g, 0.73 mmol) and *N*-hydroxysuccinimide (0.17 g, 1.5 mmol) were dissolved, and a chloroform solution (2 mL) of *N,N'*-dicyclohexylcarbodiimide (0.30 g, 1.5 mmol) was added dropwise at 2 °C under a nitrogen atmosphere. The reaction solution was stirred at room temperature for 30 min. The residue was separated by filtration and the reaction solution was condensed

under reduced pressure, with the temperature kept below 25 °C. The crude product was rinsed with ethyl acetate and acetone.

The crude product (0.66 g) was dissolved in chloroform (10 mL) in a round-bottomed flask (25 mL) and a chloroform solution (5 mL) of 1,2-dioleoyl-*sn*-glycero-3-phosphoethanolamine (0.54 g, 0.73 mmol) and triethylamine (0.10 g, 1.0 mmol) was added dropwise to the reaction solution over 20 min. The reaction mixture was stirred at room temperature for 2.5 h and the residue was separated by filtration. The obtained solution was condensed and purified using silica column chromatography with methanol/chloroform (volume ratio: 1/4-1/3). The product **6** was obtained as a green powder (0.37 g, 36%).

**5:**  $^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  (ppm) 1.90 (s, 14H); 2.54 (t, 2H); 2.75 (t, 2H); 4.25 (br, 2H); 4.38 (br, 2H); 6.34 (d, 1H); 6.52~6.68 (m, 3H); 7.44~7.59 (m, 6H); 7.76~7.97 (m, 3H); 8.01~8.10 (m, 6H); 8.20~8.29 (m, 2H); 12.6 (br, 1H).

**6:**  $^1\text{H}$  NMR (DMSO- $d_6$ ):  $\delta$  (ppm) 0.83 (t, 6H), 1.15–1.22 (m, 52H), 1.48 (t, 4H), 1.82 (q, 4H), 2.22 (t, 4H), 2.55 (m, 4H), 3.03 (q, 6H), 3.16 (t, 4H), 3.66 (quintet, 2H), 3.75 (t, 2H), 4.07 (m, 1H), 4.25 (t, 3H), 4.41 (t, 2H), 5.07 (m, 1H), 5.29 (m, 4H), 6.36 (d, 1H), 6.52–6.62 (m, 3H), 7.47 (m, 2H), 7.61–7.66 (m, 3H), 7.65 (m, 2H), 7.90–8.07 (m, 6H), 8.22 (d, 2H), 8.73 (t, 1H), 10.0 (br, 1H).

### **NMR Measurements**

The  $^1\text{H}$  NMR spectra of iDOPE (**6** in Scheme 1) and intermediate (**5** in Scheme 1) were run at 300 MHz in  $\text{DMSO-}d_6$  using a Lambda-300 NMR spectrometer (JEOL, Tokyo, Japan).

### **FTIR Measurements**

Infrared spectra of iDOPE (**6** in Scheme 1) and intermediate (**5** in Scheme 1) were recorded as potassium bromide pellets using an IRPrestige-21 spectrometer (Shimadzu, Kyoto, Japan) in the  $4000\text{--}400\text{ cm}^{-1}$  region.

### **HPLC Analysis**

iDOPE was analyzed by HPLC using a Shimadzu LC-20A chromatography system (Shimadzu, Kyoto, Japan) equipped with CHEMCOSORB 7-ODS-L ( $7\text{ }\mu\text{m}$ ,  $4.6\text{ mm} \times 150\text{ mm}$ , Chemco Scientific, Osaka, Japan). The column temperature was controlled at  $45\text{ }^\circ\text{C}$  using a CTO column oven (Shimadzu).

Eluent:  $[0.02\text{M KH}_2\text{PO}_4\text{ (pH3.0 with H}_3\text{PO}_4)/\text{CH}_3\text{OH (95/5)]/\text{CH}_3\text{OH/THF: 21/50/29}$ .

Flow rate:  $1.2\text{ mL/min}$ .

### **UV-vis-NIR and Fluorescence Spectroscopy**

The absorption spectra of iDOPE and ICG dissolved in organic solvents were obtained using a UV-vis-NIR spectrometer (UV-3500, Shimadzu, Kyoto, Japan).

Fluorescence emissions from iDOPE and ICG were observed using a fluorescence spectrometer (F-4500, Hitachi, Tokyo, Japan).

### **Singlet Oxygen Measurements**

The luminescence from singlet oxygen was measured using a high-sensitivity detection method (NIR-PII System, Hamamatsu Photonics, Hamamatsu, Japan). The excitation pulse was obtained using an optical parametric oscillator (L5996, Hamamatsu Photonics), which was excited using an Nd:YAG laser (Surelite I-20, Continuum, Santa Clara, CA, USA). The pulse width and intensity were approximately 5 ns and 300  $\mu\text{J}/\text{pulse}$ , respectively, and the repetition rate was 20 Hz. The singlet oxygen luminescence was monitored using an IR-gated image intensifier (NIR-PII, Hamamatsu Photonics) after passage through a polychromator (MS257, Oriel Instruments, Stratford, CT, USA). We began measurements at 5  $\mu\text{s}$  after excitation, and the exposure time was 100  $\mu\text{s}$ . The signals were accumulated by repeated detection (2000 times). The calibration of the wavelength was performed using a spectral calibration lamp (Krypton type, Oriel Instruments, Stratford, CT, USA).

### **Measurement of Photothermal Properties**

iDOPE and ICG in a mixed organic solvent of  $\text{CH}_3\text{OH}/\text{CHCl}_3$  (volume ratio: 1/9, 1.5 mL) in a quartz cuvette were irradiated using an 808-nm laser (LU0808T020 - E105N12A, Hanamura Optics, Yokohama, Japan) at  $0.5 \text{ W}/\text{cm}^2$ . The solution temperature was measured at 1-s intervals using an SF Series Temperature Probe (AM-8000, Anritsu Meter, Tokyo, Japan) under stirring.

## **Preparation of Liposomes**

### **1. LP-iDOPE**

Cholesterol (1.0 mM, Nippon Fine Chemical Co., Ltd., Tokyo, Japan), 1,2-dioleoyl-*sn*-glycero-3-phosphocholine (DOPC, 10 mM, NOF Corporation, Tokyo, Japan), *N*-(carbonyl-methoxypolyethyleneglycol 5000)-1,2-distearoyl-*sn*-glycero-3-phosphoethanolamine sodium salt (DSPE-PEG, 0.5 mM, NOF Corporation), and iDOPE ( $5.0 \times 10^{-5}$ ,  $1.0 \times 10^{-4}$ ,  $5.0 \times 10^{-4}$ , and  $1.0 \times 10^{-3}$  mM, iDOPE/DOPC molar ratio of 0.005, 0.01, 0.05, and 0.1) were dissolved in a mixed organic solvent of CH<sub>3</sub>OH/CHCl<sub>3</sub> (volume ratio: 1/9). A thin lipid film was formed by removal of the solvent under reduced pressure. After addition of an aqueous buffered solution (phosphate buffered saline [PBS], pH = 7.4) at room temperature, the liposome dispersion was filtered through a 0.1-mm pore polycarbonate filter attached to a LiposoFast-Stabilizer (Avestin Inc., Ottawa, Canada).

### **2. LP-ICG**

Cholesterol (1.0 mM, NOF Corporation), DOPC (10 mM, NOF Corporation), and DSPE-PEG (0.5 mM, NOF Corporation) were dissolved in a mixed organic solvent of CH<sub>3</sub>OH/CHCl<sub>3</sub> (volume ratio: 1/9). A thin lipid film was formed by removal of the solvent under reduced pressure. The dried thin lipid film, consisting of cholesterol, DOPC, and DSPE-PEG, was hydrated with PBS containing ICG ( $1.0 \times 10^{-4}$ ,  $2.5 \times 10^{-4}$ , and  $5.0 \times 10^{-4}$  mM, ICG/DOPC molar ratio of 0.01, 0.025, and 0.1) and the liposome dispersion was filtered through a 0.1-mm pore polycarbonate filter attached to a LiposoFast-Stabilizer (Avestin Inc.)

### **Gel-filtration Chromatography**

LP-iDOPE and LP-ICG were separated from free iDOPE and ICG, respectively, using PD-10 Desalting Columns containing Sephadex G-25 (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). The absorbance of the obtained fraction (1 mL) was measured using a UV-vis-NIR spectrometer (UV-1800, Shimadzu, Kyoto, Japan).

### **Measurement of Particle Size**


Particle size analysis of LP-iDOPE was performed by dynamic light-scattering measurements (SZ-100, HORIBA Ltd., Kyoto, Japan).

### **Biodistribution of iDOPE by Liposome Formulas**

Female BALB/c Slc (nu/nu) mice that were 5-6 weeks old were purchased from the Japan SLC, Inc. (Hamamatsu, Japan). Tumors were initially established by subcutaneously injecting a mixture of  $1 \times 10^7$  A549 cells (adenocarcinomic human alveolar basal epithelial cells), matrigel, and DMEM. Tumor volume was calculated  $\pi/6ab^2$ , where *a* is the length and *b* is the width of the tumor. Mice received an intravenous injection of LP-iDOPE, when the tumors reached a volume of 170 mm<sup>3</sup>. The biodistribution of LP-iDOPE was studied by injecting LP-iDOPE, containing 14.0 mg/kg of iDOPE, intravenously through a tail vein of mice bearing A549 tumors and imaged 24, 48, and 144 h after the injection with an In-Vivo MS FX PRO imaging system (Carestream Health, New York, USA)

## Results

### Molecular Modeling



**Figure S1.** Predicted three-dimensional structures of (a) ICG, (b) DOPC, and (c) iDOPE. Blue: hydrophilic region; yellow: hydrophobic region.

## NMR Measurements




Figure S2. <sup>1</sup>H-NMR spectrum of iDOPE.





Figure S3.  $^1\text{H-NMR}$  spectrum of intermediate **5** in Scheme 1.

## FTIR Measurements




**Figure S4.** FTIR spectrum of iDOPE.

**Table S1**

Observed assignments of iDOPE

Experimental Frequency ( $\text{cm}^{-1}$ )	Vibrational Assignments
2924.09	$\nu\text{CH}$
2852.72	$\nu\text{CH}$
1753.93	$\nu\text{C=O}$
1654.92	$\nu\text{C=C}, \gamma\text{CN} + \gamma\text{NH} + \nu\text{C=O}$
1527.62	$\nu\text{C=C}$
1508.33	$\nu\text{C=C}$
1089.78	$\nu\text{S-O}$

$\nu$ : stretching,  $\gamma$ : out-of-plane bending



**Figure S5.** FTIR spectrum of intermediate **5** in Scheme 1.

**Table S2**


Observed assignments of intermediate **5** in Scheme 1

Experimental Frequency (cm <sup>-1</sup> )	Vibrational Assignments
2976.16	vCH
2933.73	vCH
1718.58	vC=O
1508.33	vC=C
1421.54	vC=C
1354.03	vS(=O) <sub>2</sub>
1089.78	vS-O
923.90	γCH
665.44	γCC


v: stretching, γ: out-of-plane bending

## HPLC Analysis

(a)




(b)



**Figure S6.** HPLC chromatograms of iDOPE: (a) 254 nm and (b) 780 nm.


## Singlet Oxygen Measurements



**Figure S7.** Luminescence spectrum of singlet oxygen in oxygen-saturated  $\text{CHCl}_3$  solution of iDOPE (32  $\mu\text{M}$ , solid line). The dotted line represents the luminescence spectrum of iDOPE in the presence of  $\beta$ -carotene (6  $\mu\text{M}$ ).


The excitation wavelength was 690 nm. The pulse width and intensity were approximately 10 ns and 300  $\mu\text{J}/\text{pulse}$ , respectively, and the repetition rate was 30 Hz. Measurements were begun at 30  $\mu\text{s}$  after excitation, and the exposure time was 200  $\mu\text{s}$ . The signals were accumulated by repeated detection (1500 times).

## Dynamic Light-scattering Measurements



**Figure S8.** Diameter distribution of LP-iDOPE. iDOPE/DOPC molar ratios are 0 (blue line), 0.005 (red line), 0.01 (green line), 0.05 (black line), and 0.1 (magenta line).

## Gel-filtration Chromatograph



**Figure S9.** Gel-filtration chromatograph of (a) LP-ICG (ICG/DOPC molar ratios 0.01 and 0.1 mM of ICG) and (b) ICG (0.1 mM) on PD-10 Desalting Columns containing Sephadex G-25. Photographs of gel-filtration column were taken during the fraction tube exchange at every 1 ml elution.